Physician profile
Abdur Shakir
NPI 1669583431
$272,928.68
in general payments reported to CMS, 2019-2025
51 companies · $10K in 2025
The $10K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $48K · 2021: $44K · 2022: $64K · 2023: $48K · 2024: $10K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $26K · Consulting Fee: $26K · Travel and Lodging: $7,496 · Food and Beverage: $5,486 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,125 · Education: $1,008 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $26,300.00 |
| Consulting Fee | $26,144.00 |
| Travel and Lodging | $7,495.55 |
| Food and Beverage | $5,485.55 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,125.00 |
| Education | $1,007.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $720.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $158,035.39 | 2019-2022 | |
| G1 Therapeutics, INC. | $35,959.51 | 2022-2023 | Cosela |
| F. Hoffmann-La Roche Ag | $29,310.00 | 2022-2024 | |
| Array Biopharma INC | $24,447.43 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Roche Diagnostics International Ltd | $8,484.00 | 2025 | |
| Epizyme, INC. | $3,631.95 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $1,440.17 | 2019-2025 | |
| Pfizer INC. | $1,369.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $993.27 | 2019-2025 | Lynparza, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $980.16 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $947.33 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $764.58 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $673.44 | 2021-2025 | Xospata, Vyloy, Xtandi |
| Seagen INC. | $504.53 | 2019-2023 | Padcev, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $468.13 | 2019-2025 | Opdivo, Opdualag, Krazati |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $458.63 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $447.16 | 2019-2025 | Venclexta, Alecensa, Rozlytrek |
| Abbvie INC. | $376.17 | 2021-2025 | Venclexta |
| Incyte Corporation | $326.25 | 2019-2024 | Jakafi |
| Eisai INC. | $322.49 | 2020-2025 | |
| Gilead Sciences, INC. | $322.12 | 2019-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $275.07 | 2019-2023 | Imbruvica |
| Daiichi Sankyo INC. | $257.91 | 2021-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $246.30 | 2019-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Emd Serono, INC. | $198.78 | 2019-2025 | Bavencio |
| Genzyme Corporation | $182.47 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $123.86 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $118.90 | 2020-2025 | |
| Karyopharm Therapeutics INC. | $117.97 | 2020-2024 | Xpovio |
| Kite Pharma, INC. | $109.01 | 2020-2023 | Yescarta |
| Amgen INC. | $101.66 | 2019-2022 | |
| Taiho Oncology, INC. | $93.32 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $84.95 | 2019 | |
| Exelixis INC. | $75.97 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $68.65 | 2019-2024 | Rezlidhia, Tavalisse |
| Ipsen Biopharmaceuticals, INC | $57.93 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $53.00 | 2021-2023 | Libtayo |
| Aveo Pharmaceuticals, INC. | $49.00 | 2022-2025 | |
| Clovis Oncology, INC. | $40.06 | 2019-2020 | |
| Glaxosmithkline, LLC. | $33.21 | 2022-2023 | Ojjaara |
| Puma Biotechnology, INC. | $29.92 | 2019 | |
| Adaptive Biotechnologies Corporation | $20.87 | 2021 | |
| Recordati_rare_diseases_inc. | $20.79 | 2025 | Sylvant |
| Verastem, INC. | $18.73 | 2019 | |
| Tg Therapeutics, INC. | $17.63 | 2022 | |
| Mirati Therapeutics, INC. | $16.51 | 2023 | Krazati |
| Cti Biopharma Corp. | $16.16 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.91 | 2020 | |
| Coherus Oncology, INC. | $11.20 | 2021 | |
| Tactile Systems Technology INC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdur Shakir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.